Biocryst Pharmaceuticals (BCRX) Non-Current Deffered Revenue: 2010-2015
Historic Non-Current Deffered Revenue for Biocryst Pharmaceuticals (BCRX) over the last 5 years, with Sep 2015 value amounting to $10.1 million.
- Biocryst Pharmaceuticals' Non-Current Deffered Revenue rose 163.05% to $10.1 million in Q3 2015 from the same period last year, while for Sep 2015 it was $10.1 million, marking a year-over-year increase of 163.05%. This contributed to the annual value of $3.6 million for FY2014, which is 25.00% down from last year.
- Per Biocryst Pharmaceuticals' latest filing, its Non-Current Deffered Revenue stood at $10.1 million for Q3 2015, which was up 1.64% from $10.0 million recorded in Q2 2015.
- Biocryst Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $14.7 million for Q2 2011, and its period low was $3.3 million during Q1 2015.
- Moreover, its 3-year median value for Non-Current Deffered Revenue was $4.7 million (2013), whereas its average is $5.5 million.
- Per our database at Business Quant, Biocryst Pharmaceuticals' Non-Current Deffered Revenue slumped by 55.83% in 2012 and then skyrocketed by 163.05% in 2015.
- Quarterly analysis of 5 years shows Biocryst Pharmaceuticals' Non-Current Deffered Revenue stood at $7.1 million in 2011, then decreased by 16.65% to $5.9 million in 2012, then dropped by 20.00% to $4.7 million in 2013, then decreased by 25.00% to $3.6 million in 2014, then spiked by 163.05% to $10.1 million in 2015.
- Its Non-Current Deffered Revenue stands at $10.1 million for Q3 2015, versus $10.0 million for Q2 2015 and $3.3 million for Q1 2015.